Can Syndax Pharmaceuticals Inc. (SNDX) Add Value To Your Portfolio?


As of Wednesday close, Syndax Pharmaceuticals Inc.’s (NASDAQ:SNDX) stock was down -$0.52, moving down -2.34 percent to $21.70. The average number of shares traded per day over the past five days has been 492,780 shares. 3 times new highs have been achieved over the past 5 days, with a $0.74 gain in that time frame. In the last twenty days, the average volume was 760,140, while in the previous 50 days, it was 731,164.

Since last month, SNDX stock retreated -6.51%. Shares of the company fell to $20.71 on 11/17/22, the lowest level in the past month. A 52-week high of $26.51 was reached on 10/06/22 after having rallying from a 52-week low of $13.27. Since the beginning of this year, SNDX’s stock price has dropped by -0.87% or -$0.19, and marked a new high 6 times. However, the stock has declined by -18.14% since its 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


SNDX stock investors should be aware that Syndax Pharmaceuticals Inc. (SNDX) stock had its last reported insider trading activity 49 days ago on Oct 06. Metzger Michael A, the Chief Executive Officer of the company, disposed of 16,231 shares for $25.29 on Oct 06. It resulted in a $410,508 divestment by the insider. Katkin Keith sold 29,899 shares at an average price of $25.90 on Oct 06. The insider now owns 32,000 shares following the transaction. On Oct 04, Director Katkin Keith sold 360 shares at $25.00 apiece. The transaction was valued at $9,000.

Valuation Metrics

The stock’s beta is 1.14. Besides these, the trailing price-to-sales (P/S) ratio of 9.86, the price-to-book (PB) ratio of 3.90.

Financial Health

In the three months ended September 29, Syndax Pharmaceuticals Inc.’s quick ratio stood at 17.20, while its current ratio was 17.20, showing that the company is able to pay off its debt. Based on annual data, SNDX earned $113.49 million in gross profit and brought in $139.71 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 6.10%. Return on equity (ROE) for the past 12 months was -3.80%.

While analysts expected Syndax Pharmaceuticals Inc. to report -$0.63 quarterly earnings, the actual figure was -$0.58 per share, beating the consensus estimate by 7.90%. During the quarter, the company generated -$36.17 million in EBITDA. The liabilities of Syndax Pharmaceuticals Inc. were 21.59 million at the end of its most recent quarter ended September 29, and its total debt was $1.26 million. The value of shareholders’ equity is $60.22 million.

Technical Picture

This quick technical analysis looks at Syndax Pharmaceuticals Inc.’s (SNDX) price momentum. With a historical volatility rate of 47.70%, the RSI 9-day stood at 43.60% on 23 November.

With respect to its five-day moving average, the current Syndax Pharmaceuticals Inc. price is up by +3.53% percent or $0.74. At present, SNDX shares trade -6.34% below its 20-day simple moving average and +6.53% percent above its 100-day simple moving average. However, the stock is currently trading approximately -9.09% below its SMA50 and +42.30% above its SMA200.

Stochastic coefficient K was 26.84% and Stochastic coefficient D was 24.01%, while ATR was 1.15. Given the Stochastic reading of 29.64% for the 14-day period, the RSI (14) reading has been calculated as 43.99%. As of today, the MACD Oscillator reading stands at 0.17, while the 14-day reading stands at -0.24.

Analyst Ratings

Syndax Pharmaceuticals Inc. (SNDX) has been rated Buy by analysts. According to 0 brokerage firms, SNDX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Syndax Pharmaceuticals Inc. stock as buy, with 6 recommending it as overweight.

With a median target price of $32.00, the current consensus forecast for the stock is $29.00 – $35.00. Based on these forecasts, analysts predict Syndax Pharmaceuticals Inc. (SNDX) will achieve an average price target of $32.29.


Please enter your comment!
Please enter your name here